Lixte Cash And Short Term Investments vs Inventory Analysis

LIXTW Stock

USD 0.05 0.01 25.00%

Lixte Biotechnology financial indicator trend analysis is infinitely more than just investigating Lixte Biotechnology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lixte Biotechnology is a good investment. Please check the relationship between Lixte Biotechnology Cash And Short Term Investments and its Inventory accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Cash And Short Term Investments vs Inventory

Cash And Short Term Investments vs Inventory Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lixte Biotechnology Cash And Short Term Investments account and Inventory. At this time, the significance of the direction appears to have weak relationship.

The correlation between Lixte Biotechnology's Cash And Short Term Investments and Inventory is 0.35. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Inventory in the same time period over historical financial statements of Lixte Biotechnology Holdings, assuming nothing else is changed. The correlation between historical values of Lixte Biotechnology's Cash And Short Term Investments and Inventory is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of Lixte Biotechnology Holdings are associated (or correlated) with its Inventory. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Inventory has no effect on the direction of Cash And Short Term Investments i.e., Lixte Biotechnology's Cash And Short Term Investments and Inventory go up and down completely randomly.

Correlation Coefficient

0.35

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Lixte Biotechnology balance sheet. This account contains Lixte Biotechnology investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Lixte Biotechnology Holdings fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Inventory

Most indicators from Lixte Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lixte Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

At this time, Lixte Biotechnology's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 3.9 M in 2025, whereas Sales General And Administrative To Revenue is likely to drop 3.02 in 2025.

	2024	2025 (projected)
Interest Income	23.6K	12.4K
Gross Profit	180K	160K

Interest Income Gross Profit

Lixte Biotechnology fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant And Equipment Net	Accounts Payable	Non Current Assets Total	Other Current Assets	Property Plant And Equipment Gross	Short Long Term Debt Total	Short Term Debt	Short Term Investments	Net Receivables	Inventory	Current Deferred Revenue	Capital Surpluse
Total Assets		0.73	0.3	1.0	-0.98	-0.87	1.0	1.0	0.87	-0.3	0.88	0.3	1.0	-0.47	-0.34	0.44	0.81	-0.42	-0.34	-0.41	0.87	-0.13	-0.72	0.36	0.52	0.93
Other Current Liab	0.73		0.48	0.72	-0.65	-0.82	0.72	0.72	0.7	-0.03	0.84	0.48	0.73	-0.39	-0.31	0.38	0.67	-0.54	-0.31	-0.52	0.73	0.12	-0.53	0.36	0.81	0.73
Total Current Liabilities	0.3	0.48		0.26	-0.25	-0.5	0.27	0.29	0.33	0.16	0.47	1.0	0.3	0.04	-0.78	0.66	0.37	-0.24	-0.78	-0.15	0.32	0.32	-0.06	0.77	0.49	0.31
Total Stockholder Equity	1.0	0.72	0.26		-0.98	-0.86	1.0	1.0	0.86	-0.31	0.86	0.26	1.0	-0.47	-0.31	0.42	0.8	-0.41	-0.31	-0.4	0.87	-0.14	-0.72	0.34	0.5	0.93
Net Debt	-0.98	-0.65	-0.25	-0.98		0.83	-0.98	-0.98	-0.8	0.32	-0.79	-0.25	-0.98	0.4	0.3	-0.44	-0.8	0.43	0.3	0.23	-0.88	0.17	0.73	-0.32	-0.4	-0.91
Retained Earnings	-0.87	-0.82	-0.5	-0.86	0.83		-0.86	-0.86	-0.86	0.36	-0.96	-0.5	-0.87	0.43	0.48	-0.51	-0.77	0.3	0.48	0.43	-0.78	0.07	0.73	-0.51	-0.79	-0.88
Cash	1.0	0.72	0.27	1.0	-0.98	-0.86		1.0	0.86	-0.32	0.87	0.27	1.0	-0.47	-0.31	0.42	0.79	-0.45	-0.31	-0.41	0.87	-0.17	-0.74	0.34	0.5	0.93
Cash And Short Term Investments	1.0	0.72	0.29	1.0	-0.98	-0.86	1.0		0.86	-0.29	0.87	0.29	1.0	-0.47	-0.32	0.43	0.79	-0.45	-0.32	-0.41	0.87	-0.14	-0.72	0.35	0.5	0.93
Common Stock Total Equity	0.87	0.7	0.33	0.86	-0.8	-0.86	0.86	0.86		-0.21	0.9	0.33	0.86	-0.79	-0.21	0.32	0.87	-0.36	-0.21	-0.55	0.8	-0.08	-0.58	0.29	0.67	0.88
Common Stock Shares Outstanding	-0.3	-0.03	0.16	-0.31	0.32	0.36	-0.32	-0.29	-0.21		-0.32	0.16	-0.3	0.02	0.01	0.03	-0.2	-0.18	0.01	0.1	-0.12	0.78	0.38	-0.03	-0.3	-0.27
Other Stockholder Equity	0.88	0.84	0.47	0.86	-0.79	-0.96	0.87	0.87	0.9	-0.32		0.47	0.87	-0.53	-0.43	0.42	0.73	-0.35	-0.43	-0.64	0.75	-0.09	-0.67	0.48	0.83	0.86
Total Liab	0.3	0.48	1.0	0.26	-0.25	-0.5	0.27	0.29	0.33	0.16	0.47		0.3	0.04	-0.78	0.66	0.37	-0.24	-0.78	-0.15	0.32	0.32	-0.06	0.77	0.49	0.31
Total Current Assets	1.0	0.73	0.3	1.0	-0.98	-0.87	1.0	1.0	0.86	-0.3	0.87	0.3		-0.46	-0.34	0.44	0.81	-0.42	-0.34	-0.4	0.87	-0.13	-0.72	0.36	0.51	0.93
Common Stock	-0.47	-0.39	0.04	-0.47	0.4	0.43	-0.47	-0.47	-0.79	0.02	-0.53	0.04	-0.46		-0.31	0.13	-0.65	0.35	-0.31	0.45	-0.52	0.12	0.23	0.17	-0.43	-0.54
Property Plant And Equipment Net	-0.34	-0.31	-0.78	-0.31	0.3	0.48	-0.31	-0.32	-0.21	0.01	-0.43	-0.78	-0.34	-0.31		-0.55	-0.18	-0.09	1.0	0.11	-0.23	-0.27	0.12	-0.87	-0.29	-0.26
Accounts Payable	0.44	0.38	0.66	0.42	-0.44	-0.51	0.42	0.43	0.32	0.03	0.42	0.66	0.44	0.13	-0.55		0.4	-0.14	-0.55	-0.04	0.29	0.31	-0.54	0.49	0.26	0.41
Non Current Assets Total	0.81	0.67	0.37	0.8	-0.8	-0.77	0.79	0.79	0.87	-0.2	0.73	0.37	0.81	-0.65	-0.18	0.4		-0.4	-0.18	-0.18	0.84	-0.06	-0.53	0.26	0.52	0.84
Other Current Assets	-0.42	-0.54	-0.24	-0.41	0.43	0.3	-0.45	-0.45	-0.36	-0.18	-0.35	-0.24	-0.42	0.35	-0.09	-0.14	-0.4		-0.09	0.24	-0.51	0.17	0.29	0.03	-0.21	-0.4
Property Plant And Equipment Gross	-0.34	-0.31	-0.78	-0.31	0.3	0.48	-0.31	-0.32	-0.21	0.01	-0.43	-0.78	-0.34	-0.31	1.0	-0.55	-0.18	-0.09		0.11	-0.23	-0.27	0.12	-0.87	-0.29	-0.26
Short Long Term Debt Total	-0.41	-0.52	-0.15	-0.4	0.23	0.43	-0.41	-0.41	-0.55	0.1	-0.64	-0.15	-0.4	0.45	0.11	-0.04	-0.18	0.24	0.11		-0.18	0.08	0.28	-0.14	-0.61	-0.31
Short Term Debt	0.87	0.73	0.32	0.87	-0.88	-0.78	0.87	0.87	0.8	-0.12	0.75	0.32	0.87	-0.52	-0.23	0.29	0.84	-0.51	-0.23	-0.18		-0.08	-0.55	0.37	0.51	0.93
Short Term Investments	-0.13	0.12	0.32	-0.14	0.17	0.07	-0.17	-0.14	-0.08	0.78	-0.09	0.32	-0.13	0.12	-0.27	0.31	-0.06	0.17	-0.27	0.08	-0.08		0.17	0.22	-0.08	-0.08
Net Receivables	-0.72	-0.53	-0.06	-0.72	0.73	0.73	-0.74	-0.72	-0.58	0.38	-0.67	-0.06	-0.72	0.23	0.12	-0.54	-0.53	0.29	0.12	0.28	-0.55	0.17		-0.16	-0.4	-0.73
Inventory	0.36	0.36	0.77	0.34	-0.32	-0.51	0.34	0.35	0.29	-0.03	0.48	0.77	0.36	0.17	-0.87	0.49	0.26	0.03	-0.87	-0.14	0.37	0.22	-0.16		0.37	0.42
Current Deferred Revenue	0.52	0.81	0.49	0.5	-0.4	-0.79	0.5	0.5	0.67	-0.3	0.83	0.49	0.51	-0.43	-0.29	0.26	0.52	-0.21	-0.29	-0.61	0.51	-0.08	-0.4	0.37		0.57
Capital Surpluse	0.93	0.73	0.31	0.93	-0.91	-0.88	0.93	0.93	0.88	-0.27	0.86	0.31	0.93	-0.54	-0.26	0.41	0.84	-0.4	-0.26	-0.31	0.93	-0.08	-0.73	0.42	0.57

Click cells to compare fundamentals

Lixte Biotechnology Account Relationship Matchups

Lixte Biotechnology fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	5.2M	5.1M	5.6M	4.3M	5.0M	5.2M
Other Current Liab	10.5K	302.9K	394.8K	313.9K	360.9K	379.0K
Total Current Liabilities	216.5K	302.9K	394.8K	313.9K	360.9K	290.7K
Total Stockholder Equity	5.0M	4.8M	5.2M	4.0M	4.6M	4.8M
Net Debt	(5.1M)	(4.8M)	(5.4M)	(4.2M)	(3.8M)	(3.6M)
Retained Earnings	(30.4M)	(37.1M)	(43.4M)	(48.5M)	(43.6M)	(41.5M)
Cash	5.1M	4.8M	5.4M	4.2M	4.8M	5.1M
Cash And Short Term Investments	5.1M	4.8M	5.4M	4.2M	4.8M	5.1M
Common Stock Shares Outstanding	1.1M	1.3M	158.2K	1.9M	1.7M	1.6M
Liabilities And Stockholders Equity	5.2M	5.1M	5.6M	4.3M	5.0M	5.2M
Other Stockholder Equity	31.9M	38.4M	45.1M	49.0M	56.3M	59.1M
Total Liab	216.5K	302.9K	394.8K	313.9K	360.9K	290.7K
Total Current Assets	5.2M	5.1M	5.6M	4.2M	4.9M	5.1M
Common Stock	1.2K	1.4K	1.7K	225.0	258.75	245.81
Accounts Payable	190.3K	226.0K	229.8K	156.8K	180.3K	169.4K
Non Current Assets Total	76.9K	150.2K	147.0K	78.0K	89.7K	50.2K
Other Current Assets	159.2K	10.2K	10.4K	27.1K	31.2K	29.6K
Current Deferred Revenue	15.8K	77.0K	165.0K	157.1K	180.7K	189.7K
Net Invested Capital	1.5M	1.3M	1.7M	494.8K	569.0K	317K
Net Working Capital	5.0M	4.8M	5.2M	4.0M	4.6M	4.2M
Capital Stock	3.5M	3.5M	3.5M	3.5M	3.2M	2.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CSX	CSX Corporation
ETON	Eton Pharmaceuticals
ALLT	Allot Communications

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lixte Cash And Short Term Investments vs Inventory Analysis

Cash And Short Term Investments vs Inventory

Cash And Short Term Investments vs Inventory Correlation Analysis

Correlation Coefficient

Cash And Short Term Investments

Inventory

Lixte Biotechnology fundamental ratios Correlations

Lixte Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lixte Biotechnology fundamental ratios Accounts

Also Currently Popular

Additional Tools for Lixte Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Cash	+ 1.0	Total Stockholder Equity

Total Current Assets	- 0.98	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Net Debt	- 0.98	Total Stockholder Equity
Net Debt	- 0.98	Total Assets
Other Stockholder Equity	- 0.96	Retained Earnings